MedTrace Logo

The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients

NCT05422755 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-07-22

No results posted yet for this study

Summary

The study was conducted to assess safety and immunogenicity of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.

Conditions

  • Chronic Kidney Disease (CKD)

Sponsors & Collaborators

  • Equilab International

    collaborator UNKNOWN

  • PT. Daewoong Infion

    lead INDUSTRY

Principal Investigators

  • Nova Angginy · PT. Daewoong Infion

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422755 on ClinicalTrials.gov